On November 13, 2025, CPBIO held a significant equity acquisition signing ceremony at its headquarters in Zhengzhou, Henan, marking the successful takeover of Wuhan Huateng Jikang Biotechnology Co., Ltd.

The establishment of the new entity, Wuhan Zhengda Kangrui Biotechnology Co., Ltd., represents a key step in CPBIO's strategy to integrate high-quality industry resources and enhance its ecological layout in the animal health sector.

The ceremony was attended by senior executives from both companies. CPBIO's Chairman Ma Deshou emphasized that the acquisition is a strategic move to combine strengths, leveraging Huateng Jikang's R&D capabilities and market foundation to enhance overall competitiveness. Zhang Lei, Chairman of Huateng Jikang, expressed confidence in the merger's potential to achieve synergistic effects greater than the sum of its parts.

During the signing, key documents including the Equity Transfer Agreement and the Company Charter were formalized, outlining the governance structure of the new company. The newly appointed General Manager, Huang Song, pledged to lead the integration process efficiently, ensuring swift alignment of operations and resources.

This acquisition deepens CPBIO's strategic presence in precision animal health diagnostics and is expected to drive sustainable growth and create greater value for customers.